Revvity

RVTY · NYSE

$156.01+$5.07 (+3.36%)TodayMarket closed ·
Prev close $150.94

About RVTY

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. The company is headquartered in Waltham, Massachusetts and currently employs 11,000 full-time employees. The firm has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The segment offers instruments, reagents, software, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.

Employees
11,000
Headquarters
Waltham, Massachusetts
Listed
Jul 6, 1965
Sector
Health Care
Industry
Life Sciences Tools & Services

RVTY key statistics

Market cap
16.84B
Price-earnings ratio
72.22
Dividend yield
0.19%
Average volume
2.00M
Volume
950.52K
Open price
$152.64
High today
$157.58
Low today
$152.19
52 Week high
$166.25
52 Week low
$81.22

Revvity (RVTY) at a glance

Revvity (RVTY) last traded at $156.01, with a market cap of 16.84B, a price-to-earnings ratio of 72.22 and a dividend yield of 0.19%.

Today the stock has traded between $152.19 and $157.58. The current price is 2.5% above the day's low and 1.0% below its high.

Volume so far is 950.52K shares, below the average of 2.00M shares a day.

Over the past year Revvity has ranged from $81.22 to $166.25, and now sits 88% of the way up that range.

Revvity met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported $1.41 per share against an estimate of $1.25.

The average analyst price target is $134.53, 13.8% below the current price, from 16 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

31%of 16 analyst ratings say Buy
  • Buy31.3%
  • Hold68.8%
  • Sell0.0%
Price target · 18 analystsAvg $134.53
Low
$111.10
Now
$156.01
High
$173.25

RVTY earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 5.4% on average.

  1. Q3 FY24: reported $1.28 per share against an estimate of $1.15
  2. Q4 FY24: reported $1.42 per share against an estimate of $1.40
  3. Q1 FY25: reported $1.01 per share against an estimate of $0.9688
  4. Q2 FY25: reported $1.18 per share against an estimate of $1.16
  5. Q3 FY25: reported $1.18 per share against an estimate of $1.16
  6. Q4 FY25: reported $1.70 per share against an estimate of $1.58
  7. Q1 FY26: reported $1.06 per share against an estimate of $1.04
  8. Q2 FY26: reported $1.41 per share against an estimate of $1.25

RVTY news

  • Press releaseBusiness Wire

    Revvity Launches Signals LabGistics Solution to Connect and Orchestrate Scientific Workflows

  • Press releaseBusiness Wire

    Revvity to Present at Upcoming Investor Conferences

  • Vandana Singh

    Revvity Nears 52-Week High, but This Analyst Thinks Stock Can Climb Another 20%

  • Press releaseBusiness Wire

    Revvity to Host Investor Day

  • Press releaseBusiness Wire

    Revvity to Hold Earnings Call on November 3, 2026

  • Press releaseBusiness Wire

    Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes

  • Piero Cingari

    Fed Raises Rates, Yields Hit 2007 Highs as Fuel Costs Set Records: This Week On Wall Street

  • Piero Cingari

    10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today

Similar companies

Companies in the same industry as Revvity

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.